Accelerating the Development of New Drugs and Diagnostics Maximizing the Impact of the Cures Acceleration Network: Workshop Summary (2012) / Chapter Skim
Currently Skimming:
Appendix C: Participant Biographies
Appendix C: Participant Biographies
Pages 95-116
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 95... ...
In these capacities, she had leadership responsibility for strategic initiatives that included the Innovative Molecular Analysis Technologies for Cancer program, the Biospecimen Research Network program, and the NCI Community Cancer Centers project. She is an adjunct professor of pathology at the Johns Hopkins School of Medicine.
|
From page 96... ...
, serves on the Executive Committee of the Commission on Cancer of the American College of Surgeons, and serves as the Pathology Section Editor for Cancer. She is a past Chair of the Cancer Committee of the College of American Pathologists and was Editor of the first edition of the CAP Cancer Protocols (Reporting on Cancer Specimens)
|
From page 97... ...
He continues to serve on the Vertex Board. Prior to founding Vertex in 1989, he worked for more than a decade in pharmaceutical research at Merck, where he developed an international reputation as a leader in the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs.
|
From page 98... ...
Prior to serving as Director of OTS, Dr. Buckman-Garner served as Deputy Director for OTS and as medical team leader in the Division of Pediatric Drug Development, Office of Counter Terrorism and Pediatric Drug Development, CDER.
|
From page 99... ...
Prior to joining TVM Capital, he led drug discovery programs at Enanta Pharmaceuticals, Inc., and Mitotix, Inc. He is the author of numerous scientific publications and holds several issued and pending patents.
|
From page 100... ...
Prior to joining Amgen in 2008, she worked in clinical research and drug development in positions at the federal government, nonprofit and for-profit institutes, and companies. She was Chief Medical Officer, Insys Therapeutics, from 2007 to 2008, Director of Medical Devices and Imaging at C-Path, and Vice President of Clinical Sciences and Deputy Scientific Director at the Translational Genomics Research Institute from 2004 to 2007.
|
From page 101... ...
He is an active clinician and teacher who is board-certified in internal medicine, oncology, and infectious diseases; is Staff Physician and Infectious Diseases Consultant at both the National Naval and Walter Reed Army Medical Centers; and is adjunct professor of medicine at the University of Minnesota. Michael Gutch, Ph.D., M.B.A., had experience as both a corporate and private venture capital investor prior to joining MedImmune Ventures (MV)
|
From page 102... ...
in 1979, where he served in various scientific research positions until 1994, when he went to Emory University, Atlanta, as professor, Department of Psychiatry, Emory University School of Medicine, and Director of the Yerkes Regional Primate Research Center. As director of Yerkes, Dr.
|
From page 103... ...
He led a number of White House technology initiatives, such as the National Nanotechnology Initiative, the Next Generation Internet, bridging the digital divide, e-learning, increasing funding for long-term information technology research, making IT more accessible to people with disabilities, and addressing the growing imbalance between support for biomedical research and for the physical sciences and engineering. He was also appointed by President Clinton to serve on the G-8 Digital Opportunity Task Force (dot force)
|
From page 104... ...
He has led five candidates through Phase 2 clinical testing and has delivered five first-in-class medical countermeasures to the Strategic National Stockpile.
|
From page 105... ...
Prior to joining Pfizer, Dr. Lewis-Hall was Executive Vice President, Medicines Development of Vertex Pharmaceuticals, where she was responsible for clinical and nonclinical development as well as both medical and regulatory development; she also served as Senior Vice President of Medical Affairs at Bristol-Myers Squibb; Vice President of Research and Development at Pharmacia; and Product Team Leader at Eli Lilly & Co.
|
From page 106... ...
Ms. McGarey graduated with honors from Catholic University Law School in 1985, where she served on the Catholic University Law Review staff and was a founding co-editor of the Journal of Contemporary Health Law.
|
From page 107... ...
He is a fellow of the American Statistical Association (1985) , a member of several professional societies, a past Member of the Board of Directors of the Society for Clinical Trials, the 2002 recipient of the Marvin Zelen Leadership Award in Statistical Science, and the 2004 Lowell Reed Lecture Awardee from the American Public Health Association.
|
From page 108... ...
Projects of particular note have involved developing medical imaging for infectious diseases, infectious disease systems biology, nextgeneration research informatics, and a novel risk management strategy for BSL-4. Sudip Parikh, Ph.D., is Vice President of Health Policy at Battelle Memorial Institute and Managing Director of the Battelle Centers for Public Health Research and Evaluation.
|
From page 109... ...
Her diagnosis of breast cancer led to her interest in health research and patient advocacy, serving as Executive Vice President of the National Breast Cancer Coalition, and then as a consultant to the Director of NCI, as well as to leaders in not-for-profit advocacy organizations, foundations, and biotechnology/pharmaceutical companies.
|
From page 110... ...
from Georgetown University, where he was an editor of the Georgetown Law Review and a B.A., summa cum laude, from the University of Notre Dame, where he was elected to Phi Beta Kappa. Ellen V
|
From page 111... ...
Dr. Sung is founding chair of the Health Research Alliance, a growing consortium of private foundations and voluntary health agencies with a shared interest in fostering basic science discoveries and removing barriers that prevent them from being translated into clinical studies and then into better health.
|
From page 112... ...
He is a Fellow of the American Institute for Medical and Biological Engineering, has authored more than 190 referred publications, is the editor of 3 conference proceedings, has given more than 200 scientific presentations, and holds more than a dozen patents or patent applications. He has received three R&D 100 awards from non-volatile memories, to micro-dispensing systems, to a surrogate human immune system; the 2011 BioFlorida Company of the Year; the 2011 Florida Companies to Watch; the 2009 Outstanding Collaborator Award from DTRA; the 2009 Governor's New Product Award; the Schwartz Business Innovation Award; the Medical Marker Award; the Industry Week Innovation Award; the Discover Magazine Award; and several outstanding paper awards.
|
From page 113... ...
She has testified repeatedly before Congress and federal regulatory bodies and is a frequent speaker on the patient perspective in health policy. Before joining the Council, she held numerous senior managerial positions at the American Diabetes Association, including Vice President for Corporate Relations and Public Affairs.
|
From page 114... ...
Weingarten's leadership, the NCI SBIR Development Center has launched a range of new programs to facilitate the success of small businesses in the cancer space. One of these new initiatives is a brand new funding program for the NIH known as the SBIR Phase II Bridge Award, which more than triples the amount of funding available to applicants through the NCI SBIR Program.
|
From page 115... ...
from Duke University. H e completed a residency in internal medicine at the Massachusetts General Hospital; a cardiology fellow ship at Duke; and conducted laboratory research at Duke, Oxford University, and the Cold Spring Harbor Laboratory.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.